NVS
Novartis AG
NVS has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over NVS overall, supported by stronger fundamentals and stronger modeled upside.
NVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
NVS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $67.63 | -58% |
| Fair | 19x | $98.78 | -38% |
| Expensive | 26x | $134 | -16% |
| Current | 31x | $160 | — |
Historical ranges are pointers, not guarantees.
NVS's PE is in its expensive range at 31x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over NVS in the historical PE scenario, which offers more potential upside but is not a forecast.
NVS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for NVS, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $5.24 | -28% |
| Q2 2026 | $6.63 | -3.4% |
| Q1 2026 | $6.98 | +9.2% |
| Q4 2025 | $7.15 | +22% |
| Q3 2025 | $7.31 | -15% |
| Q2 2025 | $6.86 | -13% |
| Q1 2025 | $6.39 | -13% |
| Q4 2024 | $5.88 | -18% |
NVS's earnings per share have fallen from their peak: $5.24 over the past year, against $10.73 in early 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NVS on earnings, with more consistent year-over-year improvement.
NVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $15B | +4.7% |
| Q2 2026 | $14.4B | -2.8% |
| Q1 2026 | $13.5B | -0.7% |
| Q4 2025 | $13.3B | -1.6% |
| Q3 2025 | $14.4B | +9% |
| Q2 2025 | $14.8B | +15% |
| Q1 2025 | $13.6B | +12% |
| Q4 2024 | $13.6B | +15% |
NVS's revenue has held roughly level: $15B last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -19 points |
| Q2 2026 | 33% | +0.1 points |
| Q1 2026 | 31% | -2.9 points |
| Q4 2025 | 26% | +0.4 points |
| Q3 2025 | 31% | +3.8 points |
| Q2 2025 | 33% | +1.6 points |
| Q1 2025 | 34% | +6.4 points |
| Q4 2024 | 26% | +4.1 points |
NVS has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
NVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | -17% |
| Q2 2026 | $5.6B | -8.8% |
| Q1 2026 | $2.9B | +33% |
| Q4 2025 | $1.6B | -46% |
| Q3 2025 | $5.7B | +4.6% |
| Q2 2025 | $6.1B | +47% |
| Q1 2025 | $2.2B | +94% |
| Q4 2024 | $3.1B | +43% |
NVS's free cash flow has been positive every quarter for seven years: $14.8B over the past year, down 13% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NVS on cash flow, with more consistent year-over-year improvement.
NVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -9M shares |
| 1 year | -1.8% | -35M shares |
| 3 years | -8.2% | -170M shares |
| 5 years | -15% | -349M shares |
| Available history | -17% | -387M shares |
NVS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.7B |
| Q2 2026 | $1.2B |
| Q1 2026 | $1.9B |
| Q4 2025 | $1.5B |
| Q3 2025 | $2.3B |
| Q2 2025 | $2.7B |
| Q1 2025 | $2.7B |
| Q4 2024 | $2.8B |
NVS spent $6.2B buying back its own shares over the past year, down 40% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.8x | Healthy |
| Q2 2026 | 1.9x | Healthy |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.0x | Very low |
NVS's net debt is about 1.8 years of its operating earnings (EBITDA), up from a year a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over NVS on leverage, with a lower net debt burden relative to earnings.
NVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.3 | Neutral |
| Stochastic | 85.0 | Overbought |
NVS's weekly RSI is 57 (neutral) and its Stochastic is 85 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NVS PE vs Healthcare Sector
| Metric | NVS | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 26x | 18% above |
| PE % | 98 | 29 | 69 pts above |
NVS is trading at 31x earnings, a 18% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over NVS on valuation relative to its sector.
NVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $151.9 | 5.5% above |
| 20 week MA | $152.6 | 5% above |
| 50 week MA | $150.5 | 6.5% above |
| 100 week MA | $133.2 | 20% above |
| 200 week MA | $116.3 | 38% above |
NVS is in an uptrend: it's above all five of its weekly moving averages, and 38% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
NVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $90.3 | $83.8 | -7.2% |
| 2021 | $83.8 | $82.0 | -2.1% |
| 2022 | $82.0 | $86.0 | +4.9% |
| 2023 | $86.0 | $101.0 | +17% |
| 2024 | $101.0 | $98.4 | -2.6% |
| 2025 | $98.4 | $139.2 | +41% |
| 2026 YTD | $139.2 | $160.3 | +15% |
NVS has finished lower in three of the last six years. It's up 15% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NVS on returns for 2026, with the stronger performance.